TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the clinical development pathway for Xyndari™ for the treatment of sickle cell disease. Xyndari™ is the European brand name for the same Emmaus prescription product, Endari®, approved by the FDA and Israeli Ministry of Health.
News Ticker
- [ December 9, 2023 ] Product Release Coordinator- QA Pharmaceutical / Biotech – Full Time Days – Grifols – Los Angeles, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] “Frozen” Composer Christophe Beck and Kristen Bell Reunite at Education Through Music-Los Angeles Gala Los Angeles Biotech News
- [ December 8, 2023 ] Medical Lab Scientist – Techsara solutions Inc – Mission Viejo, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research Los Angeles Biotech News
- [ December 8, 2023 ] UCLA researchers lay groundwork to study effects of maternal diabetes on fetal metabolism and development Featured News
Copyright © 2023 Biotech Networks, LLC
